Morgan Stanley analyst David Lewis maintained a Buy rating on Stryker (SYK) today and set a price target of $215.00. The companys shares closed last Friday at $179.73.

According to TipRanks.com, Lewis is a 5-star analyst with an average return of 8.3% and a 63.1% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Stryker is a Moderate Buy with an average price target of $202.93, which is a 5.3% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $213.00 price target.

See todays analyst top recommended stocks >>

The company has a one-year high of $226.31 and a one-year low of $124.54. Currently, Stryker has an average volume of 2.42M.

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SYK in relation to earlier this year. Most recently, in March 2020, Srikant Datar, a Director at SYK bought 1,000 shares for a total of $59,700.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.

More here:

Morgan Stanley Maintains Their Buy Rating on Stryker (SYK) - Smarter Analyst